UNC Lineberger Comprehensive Cancer Center
unclineberger.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
415
Active
122
Phase 3
1
Total enrollment
135,565
Pipeline matrix
Showing 40 of 82 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Fludarabine | — | — | — | 13 | |||
| Cyclophosphamide | — | — | — | 14 | |||
| Pembrolizumab | — | — | — | 13 | |||
| Bendamustine | — | — | — | 6 | |||
| Cisplatin | — | — | — | — | 11 | ||
| Dexamethasone | — | — | — | — | — | 4 | |
| Durvalumab | — | — | — | — | 3 | ||
| ATLCAR.CD30 cells | — | — | — | — | 3 | ||
| Isatuximab | — | — | — | — | — | 2 | |
| Tirzepatide | — | — | — | — | 2 | ||
| XL092 | — | — | — | — | 2 | ||
| Carboplatin | — | — | — | — | 15 | ||
| oxaliplatin | — | — | — | — | 5 | ||
| Rituximab | — | — | — | — | 4 | ||
| Entinostat | — | — | — | — | 3 | ||
| Lenalidomide | — | — | — | — | 3 | ||
| Erlotinib | — | — | — | — | — | 3 | |
| Nab-paclitaxel | — | — | — | — | — | 3 | |
| Leucovorin | — | — | — | — | 3 | ||
| Gemcitabine | — | — | — | — | — | 2 | |
| Memantine | — | — | — | — | — | 2 | |
| Etoposide | — | — | — | — | 2 | ||
| Folfirinox | — | — | — | — | — | 2 | |
| Olomorasib | — | — | — | — | — | 1 | |
| Neoadjuvant Pembrolizumab | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | — | 1 | |
| Datopotamab deruxtecan | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Revumenib | — | — | — | — | — | 1 | |
| 5% 5-fluorouracil Topical Cream | — | — | — | — | — | 1 | |
| Trilaciclib | — | — | — | — | — | 1 | |
| Lurbinectedin | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 | |
| NALIRIFOX | — | — | — | — | — | 1 | |
| Pomalidomide | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Cell | — | — | — | — | — | 1 | |
| Atorvastatin and Lisinopril | — | — | — | — | — | 1 | |
| Short Chain Fatty Acid | — | — | — | — | — | 1 |
42 more active programs hidden
Next readouts
- 2021-01-15
- 2022-02-02
- 2023-12-15
- 2024-03-25
- 2024-07-01
- 2024-08-30
- 2024-10-16
- 2024-12-19
- 2025-04-01
- 2025-05-14
Top conditions
- Breast Cancer67
- Cancer29
- Lung Cancer20
- Lymphoma17
- Colorectal Cancer15
- Bladder Cancer14
- Prostate Cancer14
- Head and Neck Cancer13
Frequently asked questions about UNC Lineberger Comprehensive Cancer Center
- How many clinical trials does UNC Lineberger Comprehensive Cancer Center have on ClinicalTrials.gov?
- UNC Lineberger Comprehensive Cancer Center is listed as the lead sponsor on 415 clinical trials in ClinicalTrials.gov, 122 of which are currently active (recruiting, enrolling, or ongoing).
- How many of UNC Lineberger Comprehensive Cancer Center's trials are in Phase 3?
- 1 of UNC Lineberger Comprehensive Cancer Center's trials are in Phase 3, spread across 82 active drug programs.
- What therapeutic areas does UNC Lineberger Comprehensive Cancer Center focus on?
- UNC Lineberger Comprehensive Cancer Center's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Lung Cancer, Lymphoma, Colorectal Cancer.
- When are UNC Lineberger Comprehensive Cancer Center's next clinical trial readouts?
- UNC Lineberger Comprehensive Cancer Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Administration of T Lymphocytes for Prevention of Relapse of Lymphomas”, expected around 2021-01-15.